Oncothyreon (NASDAQ: [[ticker:ONTY]]), the Seattle-based cancer drug developer, said today it has begun a mid-stage clinical trial for patients with relapsed forms of brain cancer—glioblastoma multiforme. The company is testing whether its treatment, PX-866, is able to help shrink tumors in about 30 patients at seven clinical sites in Canada. The drug is designed to block the activity of the PI3 kinase, one of the hot targets in cancer biology.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
